Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center
Table 1
Clinical characteristics of the study population.
Clinical characteristics
Non-MAFLD
MAFLD
Total
Participants
1306 (36.8)
2247 (63.2)
3553 (100.0)
Male
859 (65.8)
1497 (66.6)
2356 (66.3)
Age (years)
Diabetes duration (years)
9.0 (3.1, 14.2)
5.2 (0.6, 10.6)
6.3 (1.2, 12.1)
BMI (kg/m2)
Normal weight (<24.0 kg/m2)
753 (57.7)
519 (23.1)
1272 (35.8)
Overweight (24.0-27.9 kg/m2)
471 (36.1)
1183 (52.6)
1654 (46.6)
Obesity (≥28.0 kg/m2)
82 (6.3)
545 (24.3)
627 (17.6)
PLT (109/L)
AST (U/L)
19 (16, 24)
21 (17, 21)
20 (16, 26)
ALT (U/L)
18 (13, 26)
24 (17, 35)
21 (15, 32)
ALB (g/dL)
Fasting glucose (mmol/L)
Fasting insulin (μIU/mL)
6.09 (3.83, 8.84)
8.35 (5.81, 11.72)
7.48 (4.97, 10.87)
Postprandial glucose (mmol/L)
Postprandial insulin (μIU/mL)
20.56 (12.03, 34.49)
28.09 (17.59, 45.91)
25.22 (15.45, 42.03)
TC (mmol/L)
TG (mmol/L)
1.27 (0.93, 1.78)
1.82 (1.32, 2.69)
1.60 (1.13, 2.37)
HDL (mmol/L)
LDL (mmol/L)
HbA1c (%)
HOMA-IR
2.26 (1.42, 3.63)
3.25 (2.14, 4.93)
2.88 (1.81, 4.52)
TyG index
Smoking
348 (26.6)
672 (29.9)
1020 (28.7)
Drinking
54 (4.1)
168 (7.5)
222 (6.2)
Hypertension history
496 (38.0)
938 (41.7)
1434 (40.4)
Dyslipidemia history
308 (23.6)
1040 (46.3)
1348 (37.9)
Data are expressed as , median (25th percentile, 75th percentile), or (%). MAFLD: metabolic (dysfunction)-associated fatty liver disease; BMI: body mass index; PLT: platelet; AST: aspartic acid aminotransferase; ALT: alanine aminotransferase; ALB: albumin; TC: total cholesterol; TG: triacylglycerols; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; HbA1c: glycated hemoglobin; HOMA-IR: homeostasis model assessment for insulin resistance; TyG: triglyceride-glucose index. for comparisons of MAFLD versus non-MAFLD.
